Premenstrual Syndromes : PMS and PMDD - Rutuja :: The site ...

PMS, and bilateral oophorectomy alone requires both
progestin and estrogen replacement with the risk of
re-stimulating.
CONCLUSION
Premenstrual syndrome and premenstrual dysphoric
disorder are common and often disabling conditions
affecting reproductive-aged women. A formal diagnosis
should be sought whenever premenstrual symptoms
are described. Underlying medical, psychiatric, and
psychosocial conditions should be excluded, and the
premenstrual timing and postmenstrual relief of the
symptoms documented prospectively by nightly recording
for at least two cycles. Once a definitive diagnosis is
made, initiation of various treatment strategies can be
effective in alleviating symptoms. Education, lifestyle
change, cognitive behavioral therapy, calcium supplementation,
certain hormonal oral contraceptive preparations,
and the diuretic spironolactone can be
effective. The administration of a serotonergic antidepressant
is likely to alleviate symptoms and improve
significantly the quality of life and functional status.
Luteal phase dosing is the preferred method of treatment
with SSRIs in many cases, as discontinuation
symptoms and overall side effects are minimized. The
use of GnRH analogues and estradiol patches and
implants should be reserved for the most severe cases.
REFERENCES
1. Steiner M, Hirschberg AL, Bergeron R et al. Luteal phase dosing
with paroxetine controlled release (CR) in the treatment of premenstrual
dysphoric disorder. Am J Obstet Gynecol 2005;
193(2):352–6.
2. American College of Obstetricians and Gynecologists. ACOG
Practice Bulletin: Premenstrual Syndrome. Washington, DC:
ACOG. Compendium of Selected Publications 2000; 15:1–9.
3. Rapkin AJ, Mikacich JA, Moatakef-Imani B et al. The clinical
nature and formal diagnosis of premenstrual, postpartum, and
perimenopausal affective disorders. Curr Psychiatry Rep 2002;
4:419–28.
4. Dell DL. Diagnostic challenges in women with premenstrual
symptoms. Prim Psychiatry 2004; 1:41–6.
5. American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders, 4th edn., Washington, DC:
American Psychiatric Press; 1994.
6. Connolly M. Premenstrual syndrome: an update on definitions,
diagnosis and management. Adv Psychiatr Treatment 2001;
7:469–77.
7. Ling FW. Recognizing and treating premenstrual dysphoric disorder
in the obstetric, gynecologic, and primary care practices.
J Clin Psychiatry 2000; 61:9–16.
8. Critchlow DG, Bond AJ, Wingrove J. Mood disorder history and
personality assessment in premenstrual dysphoric disorder. J Clin
Psychiatry 2001; 62:688–93.
CLINICAL EVALUATION AND MANAGEMENT 157
9. Halbreich U, Endicott J, Schacht S et al. The diversity of premenstrual
changes as reflected in the Premenstrual Assessment Form.
Acta Psychiatr Scand 1982; 65:46–65.
10. Kim DR, Gyulai L, Freeman EW et al. Premenstrual dysphoric
disorder and psychiatric co-morbidity. Arch Womens Ment
Health 2004; 7:37–47.
11. Sulak PJ, Scow RD, Preece C et al. Hormone withdrawal symptoms
in oral contraceptive users. Obstet Gynecol 2000; 95:261–6.
12. Wyatt KM, Dimmock PW, Hayes-Gill B et al. Menstrual symptometrics:
a simple computer-aided method to quantify menstrual
cycle disorders. Fertil Steril 2002; 78(1):96–101.
13. Steiner M, Streiner DL. Validation of a revised visual analog scale
for premenstrual mood symptoms: results from prospective and
retrospective trials. Can J Psychiatry 2205; 50:327–32.
14. Mortola JF, Girton L, Beck L et al. Diagnosis of premenstrual syndrome
by a simple, prospective, and reliable instrument: the calendar
of premenstrual experiences. Obstet Gynecol 1990;
76:302–7.
15. Endicott J, Nee J, Harrison W. Daily record of severity of problems
(DRSP): reliability and validity. Arch Womens Ment Health
2006; 9:41–9.
16. Freeman EW, Schweizer E, Rickels K. Personality factors in
women with premenstrual syndrome. Psychosom Med 1995;
57:453–9.
17. Pearlstein TB, Frank E, Rivera-Tovar A et al. Prevalence of axis I
and axis II disorders in women with late luteal phase dysphoric
disorder. J Affect Disord 1990; 20:129–34.
18. Wilson CA, Turner CW, Keye WR Jr. Firstborn adolescent daughters
and mothers with and without premenstrual syndrome: a
comparison. J Adolesc Health 1991; 12(2):130–7.
19. Perkonigg A, Yonkers KA, Pfister H et al. Risk factors for premenstrual
dysphoric disorder in a community sample of young
women: the role of traumatic events and posttraumatic stress
disorder. J Clin Psychiatry 2004; 65(10):1314–22.
20. Prior JC, Vigna Y, Sciarretta D et al. Conditioning exercise
decreases premenstrual symptoms: a prospective, controlled
6-month trial. Fertil Steril 1987; 47(3):402–8.
21. Girman A, Lee R, Kligler B. An integrative medicine approach
to premenstrual syndrome. Am J Obstet Gynecol 2003;
188(Suppl 5):S56–65.
22. Thys-Jacobs S, Starkey P, Bernstein D et al. Calcium carbonate
and the premenstrual syndrome: effects on premenstrual and
menstrual symptoms. Premenstrual Study Group. Am J Obstet
Gynecol 1998; 179:444–52.
23. Derman O, Kanbur NO, Tokur TE et al. Premenstrual syndrome
and associated symptoms in adolescent girls. J Obstet Gynecol
Reprod Biol 2004; 116(2):201–6.
24. Parry GJ. Sensory neuropathy with low dose pyridoxine.
Neurology 1985; 35:166–8.
25. Wyatt KM, Dimmock PW, Jones PW et al. Efficacy of vitamin
B-6 in the treatment of premenstrual syndrome: systematic
review. BMJ 1999; 318(7195):1375–81.
26. Sayegh R, Schiff I, Wurtman J et al. The effect of a carbohydraterich
beverage on mood, appetite, and cognitive function in
women with premenstrual syndrome. Obstet Gynecol 1995;
86(4 pt 1):520–8.
27. Freeman EW, Stout AL, Endicott J et al. Treatment of premenstrual
syndrome with a carbohydrate-rich beverage. Int J
Gynaecol Obstet 2002; 77:253–4.
28. Jakubowicz DL, Godard E, Dewhurst J. The treatment of premenstrual
tension with mefenamic acid: analysis of prostaglandin
concentrations. Br J Obstet Gynaecol 1984; 91:78–84.
29. Mira M, McNeil D, Fraser IS et al. Mefenamic acid in the treatment
of premenstrual syndrome. Obstet Gynecol 1986; 68:395–8.
30. Hunter MS, Ussher JM, Cariss M et al. Medical (fluoxetine) and
psychological (cognitive-behavioural therapy) treatment for